Adeno Development: Solving Challenges For Vectors That Are Easy In Theory, Complex In Practice

Translating the versatility of adenoviral vectors into a consistent current good manufacturing practice (CGMP) process requires engineering foresight during early development. While benchtop models often yield high titers, scaling to larger stirred-tank bioreactors can introduce hidden complexities in fluid dynamics, mixing, and oxygen transfer efficiency. Addressing biological and mechanical parameters—such as cell line selection, viable cell density, and metabolic kinetics—during initial shake-flask screenings builds a predictable upstream framework capable of expansion up to 500 liters without costly mid-phase re-engineering.

Upstream scale-up must be directly integrated with downstream engineering to avoid high impurity burdens. Transitioning to pilot scales increases host cell protein ratios, elevating risks of product breakthrough and membrane fouling. Implementing a stepwise purification strategy—utilizing turbidity-based clarification, automated column loading, and targeted flow-through polishing—reliably maintains a 75% viral recovery yield while achieving a 99% reduction in host cell proteins.

Access the on-demand webinar replay to gain practical insights into de-risking your adenoviral vector manufacturing program.